Cyclooxygenase-2 Genetic Variants Are Predictive of Patient Benefit: Biomarker Analyses from a Randomized Phase II Trial Evaluating Concurrent Chemoradiotherapy with or Without Celecoxib in Unresectable Stage III Non-Small Cell Lung Cancer

Authors :: N. Bi
J. Liang
Z. Zhou
D. Chen
Z. Fu
X. Yang
Z. Hui
Q. Feng
Z. Xiao
J. Lv
X. Wang
T. Zhang
L. Deng
W. Wang
J. Wang
J. Ran
L. Wang
Source :: International Journal of Radiation Oncology*Biology*Physics. 102:S16-S17
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Radiation
biology
business.industry
Genetic variants
Concurrent chemoradiotherapy
Stage III Non-Small Cell Lung Cancer
Patient benefit
Internal medicine
medicine
Celecoxib
biology.protein
Biomarker (medicine)
Radiology, Nuclear Medicine and imaging
Cyclooxygenase
business
medicine.drug

Full Text Access

Tools